Shan Zeng

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial

Sun Young Rha, Do‐Youn Oh, Patricio Yañez et al. · The Lancet Oncology · 2023 · 521 citations

Chemotherapy Versus Placebo, Gastrointestinal Oncology, Medicine +8

Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido

Vinod P. Balachandran, Michael J. Cavnar, Shan Zeng et al. · Nature Medicine · 2011 · 517 citations · Full text

Cancer Immunosurveillance, Gastrointestinal Oncology, Medicine +7

The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations

Yongsheng Ma, Shan Zeng, Dean D. Metcalfe et al. · Blood · 2002 · 447 citations · Full text

Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial

Yuankai Shi, Hang Su, Yongping Song et al. · The Lancet Haematology · 2019 · 233 citations

Lymphoid Neoplasia, Medicine, Immunotherapy +2

Lauren classification and individualized chemotherapy in gastric cancer

Junli Ma, Hong Shen, Linda Kapesa et al. · Oncology Letters · 2016 · 224 citations · Full text

Lauren Classification, Gastrointestinal Oncology, Medicine +11